Peritumoral injections of poly(I:C) induce type I IFN–dependent cytotoxic immunity and delay the growth of primary and transplanted Hgf-Cdk4R24C melanomas.

Slides:

Advertisements

Similar presentations

A Novel Cancer Therapeutic Using Thrombospondin 1 in Dendritic Cells

Advertisements

AF647-RIS is internalized by TAMs in vivo.

Synergistic antitumor effect of anti-CD40/CpG and 14

Antitumor effect of the combination of IL-2 IC and anti–CTLA-4.

Selinexor combines with immune checkpoint blockade to slow B16F10 melanoma tumor growth. Selinexor combines with immune checkpoint blockade to slow B16F10.

Treatment with BLU9931 leads to tumor regression in the FGF19-overexpressing PDX-derived xenograft LIXC012. Treatment with BLU9931 leads to tumor regression.

Attenuated MDSC-suppressive activity and metastasis development in IDO-deficient mice is rescued by IL-6. Attenuated MDSC-suppressive activity and metastasis.

Cytotoxic therapy induces macrophage recruitment, as well as CSF1 and IL-34 mRNA expression. Cytotoxic therapy induces macrophage recruitment, as well.

Effects of SC144 on in vivo ovarian tumor.

H31m1-PDL1 cells form progressively growing tumors in WT mice.

Level of EGFR inhibition determines cell death response in EGFR mutant GBM cells. Level of EGFR inhibition determines cell death response in EGFR mutant.

Treatment with BLU9931 leads to tumor regression in the FGF19-amplified Hep 3B liver cancer model. Treatment with BLU9931 leads to tumor regression in.

The EGF receptor confers BRAF inhibitor resistance in BRAF-mutant melanoma cells. The EGF receptor confers BRAF inhibitor resistance in BRAF-mutant melanoma.

Antitumor effect of local cancer immunotherapy treatment toward distant B16F10 tumors. Antitumor effect of local cancer immunotherapy treatment toward.

Epithelial loss of TβRII results in increased Th17 cell development.

Anti-CD96 combines with anti–CTLA-4 or anti–PD-1 to suppress experimental and spontaneous lung metastases. Anti-CD96 combines with anti–CTLA-4 or anti–PD-1.

Figure 3 TRIF deficiency abrogates the immunomodulatory effects of glatiramer acetate treatment on cytokines and experimental autoimmune encephalomyelitis.

Highly related T9 and T3 sarcoma cells show distinct tumor growth patterns but similar PD-L1 expression kinetics in vivo. Highly related T9 and T3 sarcoma.

Administration of necroptosis-targeting AAVs in conjunction within vivo promotes durable tumor clearance. Administration of necroptosis-targeting AAVs.

PMPs survive STZ cytotoxicity and produce larger colonies with a higher yield of insulin+ progeny. PMPs survive STZ cytotoxicity and produce larger colonies.

PTX in combination with PLX397 induces antitumor T-cell response.

L-ICON1 is effective for the treatment of murine TNBC (4T1/Luc + GFP) in an orthotopic CDX model. L-ICON1 is effective for the treatment of murine TNBC.

CT-26 colon cancer induces the recruitment of protumor mast cells and the accumulation of MDSCs. CT-26 colon carcinoma cells (2 × 105) were injected s.c.

PTENP1 serves as a ceRNA in the regulation of tumor growth in RCC

PTENP1 sensitizes renal cancer cells to chemotherapy.

Conversion of CD11bhighCD27high NK cells into MDSCs leads to CD11bhighCD27high and CD11bhighCD27low NK cell reduction. Conversion of CD11bhighCD27high.

CD49b+ cells from tumor-bearing mice are more prone to conversion into MDSCs compared with naive CD49b+ cells. CD49b+ cells from tumor-bearing mice are.

PD-L1 expression correlates with T-cell markers and an IFN response signature in human melanomas. PD-L1 expression correlates with T-cell markers and an.

MMP-1 functionally contributes to HEp3-hi/diss intravasation and metastasis. MMP-1 functionally contributes to HEp3-hi/diss intravasation and metastasis.

Immune signatures of patients with short-, medium-, and long-term survival. Immune signatures of patients with short-, medium-, and long-term survival.

A Novel Cancer Therapeutic Using Thrombospondin 1 in Dendritic Cells

Overexpression of DDB2 reduces invasive abilities in lungs of aggressive breast tumor cells. Overexpression of DDB2 reduces invasive abilities in lungs.

PD-L1 expressed on edited T3 sarcoma cells prevents their immune elimination. PD-L1 expressed on edited T3 sarcoma cells prevents their immune elimination.

IDO deficiency delays the development of pulmonary metastases.

Induction of a tumor-specific immune response following radiofrequency ablation (RFA). Induction of a tumor-specific immune response following radiofrequency.

5FU-induced specific activation of CD8+ T cells.

Irradiated whole-cell vaccination with MOC1, but not MOC2, induces immunologic memory. Irradiated whole-cell vaccination with MOC1, but not MOC2, induces.

ESKM is superior to ESK1 in vivo, and is effective against multiple tumor models. ESKM is superior to ESK1 in vivo, and is effective against multiple tumor.

FcRγ signaling regulates BTK activation and mediates PDAC growth.

GM-CSF is required for CA-MSC–induced tumor metastasis.

Influenza vaccine enhances NK cell function through IFN-α.

Bortezomib induces an NRF2 signature and NRF2 protein in tumor cells from leukemic MCL. Gene sets regulated by bortezomib (Supplementary Tables S3 and.

Essential role for the overexpression of type I IFN-related genes in the improved chemotherapeutic response of Stat3−/− tumors. Essential role for the.

NT157 treatment inhibits LNCaP xenograft growth and delays castration-resistant progression. NT157 treatment inhibits LNCaP xenograft growth and delays.

HMQ1611 inhibited breast tumor growth in mice.

The CD8+ cytotoxic T-cell response in Ron TK−/− hosts in response to tumors is necessary and sufficient to block metastasis. The CD8+ cytotoxic T-cell.

A to C, MetMAb shows strong antitumor activity in the KP4 orthotopic model of pancreatic cancer by ultrasound. A to C, MetMAb shows strong antitumor activity.

Tumor-resident CD8+ T cells rapidly expand after IL-15/IL-15Rα complex treatment. Tumor-resident CD8+ T cells rapidly expand after IL-15/IL-15Rα complex.

Pdcd4 expression inhibits AP-1 transactivation.

Comparison of in vivo activity of 4D5scFvZZ and 4D5scFv.

Tumor protection induced by therapeutic PLG vaccination in combination with blockade antibodies. Tumor protection induced by therapeutic PLG vaccination.

Anti-CD40 activates TAMs and recruits inflammatory monocytes.

Expression of IFN-λs, IFN-λR1, and IL-10R2 in Xenopus tissues after stimulation in vivo with poly(I:C). Expression of IFN-λs, IFN-λR1, and IL-10R2 in Xenopus.

Efficacy of KM100 and/or MTX in BALB/c mice bearing subcutaneous TUBO tumors. Efficacy of KM100 and/or MTX in BALB/c mice bearing subcutaneous TUBO tumors.

Effect of MZ treatment on lung colony formation in an experimental metastasis. Effect of MZ treatment on lung colony formation in an experimental metastasis.

Immune checkpoint molecule expression in primary and secondary tumors following radiotherapy. Immune checkpoint molecule expression in primary and secondary.

Antibody-mediated blockade of the immune-inhibitory PD-1–PD-L1 signaling pathway prolongs survival in poly(I:C)-treated mice. Antibody-mediated blockade.

Increased growth factor receptor expression in lungs and tumors of hypoxic mice. Increased growth factor receptor expression in lungs and tumors of hypoxic.

Intratumoral injections of small doses of agonist anti-CD137 mAb to directly act on CD137+ TILs render systemic immunotherapeutic effects that are synergistic.

In vivo shRNA screening in PDXs from 3 patients with melanoma.

Increased tumorigenic activities of TIM-3–expressing RCC cells.

Mechanism by which flavopiridol induces cell cycle arrest and apoptosis in rhabdoid tumor cells. Mechanism by which flavopiridol induces cell cycle arrest.

VEGF-A inhibition impedes proliferation in Amppos tumors.

Transgenic mice with constitutively active NIK show increased tumor growth in bone. Transgenic mice with constitutively active NIK show increased tumor.

Induction of PD-1 in B cells by TLR agonists and primary HCC-SN.

Recruitment of CD8+, CD4+, and Foxp3+ cells into oral lesions in response to anti–PD-1 treatment. Recruitment of CD8+, CD4+, and Foxp3+ cells into oral.

Cell counts of immune infiltrate and expression of galectin-1 and galectin-3 in the short-, medium-, and long-term survival cohorts. Cell counts of immune.

Curative effect of W+T treatment in vivo.

Wnt5A and ROR2 contribute to intrinsic resistance to BRAF inhibitors.

Knockdown of ROR1 increases the invasive potential of melanoma cells in vitro and in vivo. Knockdown of ROR1 increases the invasive potential of melanoma.

Presentation transcript:

Peritumoral injections of poly(I:C) induce type I IFN–dependent cytotoxic immunity and delay the growth of primary and transplanted Hgf-Cdk4R24C melanomas. Peritumoral injections of poly(I:C) induce type I IFN–dependent cytotoxic immunity and delay the growth of primary and transplanted Hgf-Cdk4R24C melanomas. Primary DMBA-induced (A–F) and intracutaneously (i.c.) transplanted (F–J) Hgf-Cdk4R24C melanoma model. A and F, experimental protocols for short-term treatment of melanomas with poly(I:C). B and G, fold increase of mRNA expression levels for the indicated genes (left) and of the percentage of tumor-infiltrating immune cells (right) in primary and transplanted Hgf-Cdk4R24C melanomas compared with controls (mean ± SEM; n = 6). C and H, experimental protocols for long-term treatment of melanomas with poly(I:C). D and I, tumor growth kinetics of melanomas in individual mice treated as indicated (left, middle), and mean survival in each cohort (right; mean ± SEM; n = 6; **, P < 0.01). Similar results were obtained in two independent treatment cohorts. E and J, corresponding tumor growth kinetics and mean survival in Ifnar1-deficient cohorts of mice treated as indicated (n = 6). Similar results were obtained in two independent treatment cohorts. Tobias Bald et al. Cancer Discovery 2014;4:674-687 ©2014 by American Association for Cancer Research